Medpace Holdings Inc (MEDP)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $18.29B
Last updated: Nov 17, 2026 at 4:23 PM ET
Medpace Holdings Inc (MEDP) Statistics
Medpace Holdings (MEDP) has a market cap of $18.29B and an enterprise value of $17.59B. Revenue grew 20.35% over the last 12 months from the 12 months before. Its trailing P/E of 36.2x is above its 10-year median of 28.9x.
Total Valuation
Enterprise value is 3.86% below the market cap, as cash exceeds debt.
| Market Cap | $18.29B |
|---|---|
| Enterprise Value | $17.59B |
| Latest price (Nov 17, 2026) | $653.09 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.4x and 31.2x. Its year-end P/E ranged from 20.4x to 44.3x from 2017 to 2025.
| P/E Ratio | 36.2x |
|---|---|
| Forward P/E | 35.1x |
| P/S Ratio | 6.4x |
| Forward P/S | 6.4x |
| P/B Ratio | 31.2x |
| P/FCF Ratio | 27.3x |
| P/OCF Ratio | 25.3x |
| PEG Ratio | 3.5 |
Enterprise Valuation
Counting debt and cash, the company is valued at 27.6x EBITDA and 26.3x free cash flow.
| EV / Earnings | 34.0x |
|---|---|
| EV / Sales | 6.2x |
| EV / EBITDA | 27.6x |
| EV / FCF | 26.3x |
Price Statistics
The stock is up 10.68% over 52 weeks and trades 3.35% above its 50-day average.
| Beta (1Y) | 0.69 |
|---|---|
| 52-Week Change | +10.68% |
| 1-Month Change | +5.39% |
| 3-Month Change | +7.37% |
| 6-Month Change | +55.53% |
| 5-Year Change | +187.80% |
| 10-Year Change | +2146.76% |
| Total Return (1Y) | +10.68% |
| Total Return (3Y CAGR) | +33.57% |
| Total Return (5Y CAGR) | +23.63% |
| Return vs SPY (1Y) | -0.90% |
| Max Drawdown (1Y) | -36.61% |
| Max Drawdown (3Y) | -39.38% |
| Sharpe Ratio (1Y) | 0.22 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $631.90 |
| 200-Day Average | $532.67 |
| 52-Week Range | $373.00 to $693.97 |
| RSI (14 Days) | 51.7 |
| Average Volume (20 Days) | 294.26K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.83x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.83x |
|---|---|
| Quick Ratio | 0.83x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 88.53% over the last 12 months, against a 5-year average of 56.09%.
| Return on Equity (ROE) | 88.53% |
|---|---|
| Return on Assets (ROA) | 22.49% |
| ROE (5Y Average) | 56.09% |
| ROA (5Y Average) | 17.65% |
| ROIC (5Y Average) | 95.95% |
| Asset Turnover | 1.40x |
| Receivables Turnover | 6.38x |
Taxes
Income tax took 17.41% of pretax income over the last 12 months.
| Income Tax (TTM) | $109.17M |
|---|---|
| Effective Tax Rate | 17.41% |
Scores
MEDP has an Altman Z-Score of 8.12, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.12 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $2.84B over the last 12 months.
| Revenue | $2.84B |
|---|---|
| Revenue Growth (YoY) | +20.35% |
| Gross Profit | $2.84B |
| Operating Income | $607.14M |
| Pretax Income | $626.99M |
| Net Income | $517.83M |
| EBITDA | $635.15M |
| Reported EPS (TTM) | $18.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 25.43% of the $2.30B in total assets.
| Cash and Equivalents | $705.32M |
|---|---|
| Total Debt | $0 |
| Net Cash | $705.32M |
| Net Cash Per Share | $25.24 |
| Working Capital | -$251.10M |
| Shareholder Equity | $584.94M |
| Book Value Per Share | $20.94 |
| Tangible Book Value | -$110.41M |
| Total Assets | $2.30B |
| Total Liabilities | $1.72B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $55.42M of capital spending, operating cash flow left $667.63M of free cash flow.
| Operating Cash Flow | $723.05M |
|---|---|
| Capital Expenditures | $55.42M |
| Free Cash Flow | $667.63M |
| FCF Per Share | $23.87 |
| Depreciation and Amortization | $27.33M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 21.39%, against a 5-year average of 19.33%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 21.39% |
| Pretax Margin | 22.09% |
| Net Margin | 18.24% |
| EBITDA Margin | 22.38% |
| FCF Margin | 23.52% |
| Operating Margin (5Y Average) | 19.33% |
| Net Margin (5Y Average) | 16.94% |
Growth
Revenue grew 20.12% a year over 3 years, and EPS 27.51% a year.
| Revenue Growth (3Y CAGR) | +20.12% |
|---|---|
| Revenue Growth (5Y CAGR) | +22.27% |
| EPS Growth (3Y CAGR) | +27.51% |
| EPS Growth (5Y CAGR) | +30.97% |
| FCF Growth (3Y CAGR) | +24.76% |
| FCF Growth (5Y CAGR) | +24.57% |
| Operating Income Growth (3Y CAGR) | +24.28% |
| Book Value Per Share Growth (2Y CAGR) | -5.00% |
Dividends and Yields
MEDP does not pay a dividend. Its free cash flow yield is 3.66%.
| Earnings Yield | 2.76% |
|---|---|
| FCF Yield | 3.66% |
| Buyback Yield | 1.62% |
| Shareholder Yield | 1.62% |
Peer Position
Against 11 similar companies, MEDP has the 5th highest P/E.
P/E RatioPeer median 26.6x
P/S RatioPeer median 4.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.27%
| P/E Ratio | 36.2x vs 26.6x median |
|---|---|
| P/S Ratio | 6.4x vs 4.4x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +20.35% vs +6.27% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.27% and EPS growth at 13.92% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.27% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +13.92% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MEDP
What is MEDP's market cap?
Medpace Holdings has a market cap of $18.29B. Its enterprise value, which adds debt and subtracts cash, is $17.59B.
What is MEDP's P/E ratio?
Medpace Holdings has a trailing P/E ratio of 36.2x and a forward P/E of 35.1x.
How many shares of MEDP are outstanding?
Medpace Holdings has 27.94M shares outstanding. The count is down 0.70% from a year earlier.
Does MEDP pay a dividend?
No. Medpace Holdings does not pay a dividend.
How much debt does MEDP have?
Medpace Holdings has $0 of total debt and $705.32M of cash and equivalents, a net cash position of $705.32M.
MEDP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors